Alira Health Expands Its Global Clinical and Data Capabilities Through the Acquisition of CROS NT
Alira Health (www.alirahealth.com ), a leading international healthcare and life sciences advisory services firm, announced that it has acquired CROS NT (www.crosnt.com ), a data-driven Contract Research Organization (CRO) headquartered in Italy with offices across Europe and the United States. CROS NT provides high quality, cost-effective biometrics and innovative solutions to help clients develop and deliver therapeutics and diagnostics that improve patient lives around the world. This acquisition brings additional expertise to Alira Health’s full spectrum of advisory and implementation services that help providers, payers and suppliers uncover opportunity, accelerate innovation, and improve outcomes for patients.
“We are extremely pleased to acquire CROS NT’s Biometrics services globally. The synergies among our Regulatory, Clinical and Real-World Evidence (RWE) practices and CROS NT’s global biometrics capabilities will enhance Alira Health’s unique ability to serve clients across their solutions lifecycle,” said Gabriele Brambilla, Chief Executive Officer at Alira Health. “The addition of CROS NT will also enable Alira Health to expand our direct clinical operations in Europe. We embrace CROS NT’s commitment and passion to being a visionary in clinical research and are proud to welcome CROS NT CEO, Paolo Morelli, and his team to our fast-growing company.”
“CROS NT is delighted to join Alira Health to better serve our clients by providing a complete portfolio of services and solutions. We are excited to contribute to Alira Health’s mission of healthcare transformation, creating value for patients,” said Paolo Morelli, CEO of CROS NT. “Our experienced team of professionals will deliver value through our combined services, accelerating innovation and delivering tomorrow’s standard of care to patients.”
Paolo Morelli will join Alira Health’s leadership as Executive Vice President, Biometrics, and will lead the growth of Alira Health’s Data Science services.
About CROS NT:
CROS NT is a global biometrics service provider with 28+ years of experience in business, focused on clinical and observational trials. In addition, we support our clients with a full-service clinical offering delivered through a network of trusted partners.
CROS NT has offices in Bologna and Verona, Italy; London, England; Chapel Hill, NC, U.S.
Learn more at https://crosnt.com/ .
About Alira Health:
Alira Health is an international advisory firm on the frontlines of healthcare transformation. We provide a suite of integrated services designed to help healthcare and life science companies innovate and grow across their solutions lifecycle.
Alira Health was founded in 1999 and is based in Framingham, MA, U.S. Offices are located in San Francisco, CA, U.S.; Paris, France; Barcelona, Spain; Munich, Germany; Milan, Italy; and Basel and Geneva, Switzerland.
Learn more at https://www.alirahealth.com/ .
About Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NORTHLEAF-CAPITAL22.6.2021 20:02:10 CEST | Press release
Northleaf Appoints Shane Feeney to Lead and Expand Its Well-established Global Secondaries Business
SES22.6.2021 18:48:06 CEST | Press release
SES Successfully Prices EUR 150 Million Tap of 2026 Eurobond
PMC-ORGANOMETALLIX22.6.2021 18:37:05 CEST | Press release
Safic-Alcan Extends Its Distribution Agreement With PMC Organometallix to the African Continent
CA-XPRIZE22.6.2021 18:26:04 CEST | Press release
In Celebration of World Rainforest Day, 33 Qualified Teams and 9 Judges Announced in $10M XPRIZE Competition to Improve Understandings and Preservation of the Planet’s Rainforests
BOURSEINSIDE22.6.2021 17:10:10 CEST | Press release
BourseInside, The New Media Platform That Finds Attractive Investments for Curious Investors
JANSSEN22.6.2021 16:33:06 CEST | Press release
DARZALEX®▼ (daratumumab) Subcutaneous (SC) Formulation Becomes the First Approved Treatment for Newly Diagnosed Systemic Light Chain Amyloidosis in Europe and Gains an Additional Approval in Pre-Treated Multiple Myeloma
PPG22.6.2021 15:04:40 CEST | Press release
PPG Introduces Digital Color-Matching Device for Commercial Vehicles
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom